QNTM
Quantum BioPharma Ltd. (QNTM) SWOT Analysis Analysis (2026)
Strengths
Low leverage and a current ratio above 1.2 support balance-sheet flexibility versus more indebted peers, reducing refinancing pressure.
Quick ratio near 1.2 indicates near-term liquidity coverage is adequate, which is stronger than weaker-capitalized peers facing tighter working-capital constraints.
Cash conversion cycle of 77 days is manageable for a capital-intensive business, though it remains less efficient than best-in-class peers with faster turnover.
Weaknesses
Negative ROIC indicates capital deployment is destroying value versus profitable peers, limiting structural earnings power over a full cycle.
The absence of positive margin disclosure alongside negative ROIC suggests weak operating leverage, leaving QNTM behind peers with durable profitability.
A 77-day cash conversion cycle ties up cash longer than efficient peers, which constrains reinvestment capacity and raises working-capital drag.
Opportunities
If management improves capital efficiency, even modest ROIC gains would materially narrow the gap versus peers because the current base is deeply negative.
Working-capital optimization could release cash and improve flexibility, creating a clearer path to peer-level liquidity efficiency over the next 2–5 years.
A stronger balance sheet than leveraged peers provides optionality for operational improvement, which could matter more if industry conditions normalize.
Threats
Persistently negative ROIC leaves QNTM vulnerable to peers that compound capital at positive returns, widening the long-term positioning gap.
Longer cash conversion than efficient competitors can pressure liquidity during demand softness, especially if peers convert sales to cash faster.
If margin structure remains undisclosed or weak, peers with clearer profitability advantages may continue to attract capital and customer confidence.
Overall Score
QNTM’s modest liquidity and low leverage are outweighed by negative capital returns and weaker operating efficiency versus peers, leaving its structural positioning weak.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Quantum BioPharma Ltd.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

